skip to main content

    Updated Visitor Guidelines

 

MENU

 

Female doctors twice as likely to screen low-risk women for cervical cancer with HPV test

For low-risk women, the likelihood that they get tested for the infection that causes cervical cancer (human papillomavirus or HPV) may depend on what clinic they visit, their doctor's status and whether their provider is male or female, a University of Michigan Health System study shows.

Researchers unravel mystery of how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts

Researchers at the Children's Medical Center Research Institute at UT Southwestern, the University of California at San Francisco and the University of Michigan Rogel Cancer Center have discovered how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts.

Dulexetine helps relieve pain from chemotherapy, study finds

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59% of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

U-M scientists say fused genes trigger the development of prostate cancer

Gene fusions trigger cancer growth, could impact treatment choices.

New drug cuts risk of deadly transplant side effect in half

Researchers at the University of Michigan Rogel Cancer Center have discovered a new class of drugs which reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments.

A path to lower-risk painkillers: Newly-discovered drug target paves way for alternatives to morphine

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Rogel Cancer Center researchers are reporting.

U-M study finds overtreatment prevalent in patients with early stage breast cancer

Written by Justin Harris, Phone: 734-764-2220, E-mail: [email protected].

Many patients with low risk for recurrence still undergo advanced diagnostic imaging to look for metastasis

ANN ARBOR, Mich. - Limiting advanced imaging tests such as CT scans for patients with early stage breast cancer can improve the quality and reduce the cost of care, yet a new University of Michigan Rogel Cancer Center study shows many patients still receive such tests despite being at low risk for recurrence.

New Gift from Valerie Trotman Seeks to Ease Cancer's Emotional Toll

The information on this page has expired. To learn about supporting the University of Michigan, please visit the Leaders and Best website.

New, Non-Invasive Prostate Cancer Test Now in Use at Michigan Medicine

The information on this page has expired. To learn about more recent advancements in research at the U-M Rogel Cancer Center, visit our news archive.

Pages